CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Follow-Up Questions
Quel est le ratio P/E de CureVac NV (CVAC) ?
Le ratio P/E de CureVac NV est de 6.324
Quelle est la performance du prix de l'action CVAC ?
Le prix actuel de CVAC est de $5.38, il a increased de 0.37% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de CureVac NV ?
CureVac NV appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de CureVac NV ?
La capitalisation boursière actuelle de CureVac NV est de $1.2B
Est-ce que CureVac NV est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 8 analystes ont établi des notations d'analystes pour CureVac NV, y compris 2 achat fort, 4 achat, 7 maintien, 0 vente et 2 vente forte
